Furthermore, we verified this result in Roper cohort, correspondence with the former cohorts, CCL5 indicates better survival in SCLC patients accepting immunotherapy (Figure 2F), as well as an independent protective factor (Figure 2E). Here, CCL5 is linked to small cell lung carcinoma.